PRRT2 and ovarian carcinoma: Therefore, although TSHR signaling has not yet been well characterized in the ovarian cancer cells, one may speculate that it can also activate the calcium and PKC pathways, which may then contribute to at least part of the thyrostimulin-induced ERK activation.